Ferric Carboxymaltose in Subjects With Functional Iron Deficiency

Status Completed

Clinical Trial Summary

Anaemia and functional iron deficiency are common conditions in patients with lymphoid malignancies, conditions which reduce significantly the quality of life and increase morbidity and mortality. Traditionally, Erythropoiesis Stimulating Agents (ESAs) have been used, but recently their use has been shown to have a negative impact on overall survival in different oncology populations. Recently published data suggest that intravenous (IV) iron can be effective in anaemia treatment, even without ESAs. This exploratory study is the first clinical project with ferric carboxymaltose (FCM) in patients with lymphoid malignancies: the data generated may be used for further evaluations of the drug in larger populations. In this study, 1,000 mg of IV iron as FCM will be administered on the same day or within 24 hours before or after chemotherapy treatment. The primary objective is to evaluate the efficacy of FCM in the correction of haemoglobin levels in anaemic subjects with lymphoid malignancies, undergoing chemotherapy. Secondary objectives aim to describe the safety and tolerability of FCM, and the effect of FCM treatment on iron status variables in subjects suffering from lymphoid malignancies.

Clinical Trial Description

Multicentre, randomised, controlled, 2-arm open-label prospective pilot study to evaluate efficacy and safety of FCM in the treatment of anaemia in LPD subjects with functional iron deficiency (FID), undergoing chemotherapy. The subjects will be screened for eligibility within 4 weeks prior to inclusion to receive intravenous (IV) infusions of FCM or no FCM infusions (the subjects may be treated according to the local institutional practice if requiring symptomatic management of anaemia). After randomisation, the visits are scheduled weekly until Week 8. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01101399
Study type	Interventional
Source	Vifor Inc.
Contact
Status	Completed
Phase	Phase 3
Start date	May 2010
Completion date	November 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04949165` - Bloodsafe Ghana- Iron and Nutritional Counseling Strategy Pilot Study	N/A
Active, not recruiting	`NCT02541708` - IV Ferric Carboxymaltose Compared With Oral Iron in the Treatment of Iron Deficiency Anemia at Delivery in Tanzania	Phase 3
Completed	`NCT01942460` - Ferumoxytol for Iron-Deficiency Anemia in Chronic Kidney Disease and Peritoneal Dialysis Patients	Phase 4
Completed	`NCT01047098` - Effects of Taking Prenatal Vitamin-mineral Supplements During Lactation on Iron Status and Markers of Oxidation	N/A
Completed	`NCT00810030` - FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR	Phase 3
Completed	`NCT00298051` - Umbilical Cord Clamping and Infant Iron Status	N/A
Completed	`NCT01135576` - Iron Fortified Beverages and Application in Women Predisposed to Anemia	N/A
Withdrawn	`NCT04320966` - Neurovascular Complications and White Matter Damage in Acquired Anemias
Completed	`NCT05240677` - Endoscopy in CKD With Iron Deficiency Anemia	N/A
Terminated	`NCT01100879` - Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy	Phase 4
Recruiting	`NCT02487719` - Different Iron Supplements for Prevention of Anemia in Pregnancy	Phase 4
Recruiting	`NCT03232554` - Buxue Yimu Pills for Gynecological Iron-Deficiency Anemia	Phase 2
Terminated	`NCT02341300` - Use of Cast Iron Pots to Improve Maternal Anemia	N/A
Completed	`NCT04318405` - Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE).
Completed	`NCT02998697` - Short Term Oral Iron Supplementation in Systolic Heart Failure Patients Suffering From Iron Deficiency Anemia	Phase 2/Phase 3
Not yet recruiting	`NCT03411590` - The Effect of Fortified Growing-up Milk on Growth and Micronutrient Status of Nigerian Toddlers	N/A
Completed	`NCT05365308` - EHR-based Patient Identification and Panel Management of Patients With Iron Deficiency Anemia	N/A
Recruiting	`NCT01071759` - Effects of Dietary Heme/Non-heme Iron and Helicobacter Pylori (Hp) Infection on Maternal Iron-deficiency Anemia and Fetal Growth Outcomes	N/A
Terminated	`NCT00882414` - Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD)	Phase 2
Completed	`NCT02968368` - Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Ferric Carboxymaltose in Subjects With Functional Iron Deficiency Undergoing Chemotherapy — FID-CHEMO

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms